Repackaging FDA-approved drugs for degenerative diseases: Promises and challenges

Expert Review of Clinical Pharmacology

Volumn 7, Issue 2, 2014, Pages 161-165

  Cummings, Jeffrey L ^a   Zhong, Kate ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

Alzheimer's disease; brain; drug development; drug repurposing; neurodegenerative disease

Indexed keywords

ALZHEIMER DISEASE; DRUG APPROVAL; DRUG DESIGN; DRUG REPOSITIONING; HUMANS; INTELLECTUAL PROPERTY; NEURODEGENERATIVE DISEASES; PATENTS AS TOPIC; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894211326     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.884923     Document Type: Review

References (17)

1. Paul SM, Lewis-Hall F. Drugs in search of diseases. Sci Transl Med 2013;5:186fs18
2. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-6
3. Loakeimidis N, Kostis JB. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. J Cardiovasc Pharmacol Ther 2014;19: 53-64
4. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9: 203-14
5. Scott TJ, O'Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities of accelerate Alzheimer's research and development. New York Academy of Sciences. RTI International; Research Triangle Park, NC, USA; 2013
6. Arrowsmith J, Miller P. Trial watch: Phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 2013;12:569
7. Wang J, Zhao Z, Lin E, et al. Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. PLoS One 2013;8:e65232
8. Appleby BS, Nacopoulos D, Milano N, et al. A review: Treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 2013;35:1-22
9. Appleby BS, Cummings JL. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem 2013;13:2306-27
10. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2013;11:833-46
11. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012;109: E2895-903
12. Valenzuela M, Esler M, Ritchie K, Brodaty H. Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. Transl Psychiatry 2012;2:e107
13. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730-6
14. Huang R, Southall N, Wang Y, et al. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011;3:80ps16
15. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003;3:90-105.51
16. Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov 2013;12:87-90
17. Oprea TI, Nielsen SK, Ursu O, et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inf 2011;30:100-11